ProCE Banner Series

Expert Perspectives on the Evolving Treatment of EGFR-Mutated Advanced and Metastatic NSCLC

In this live satellite symposium, a panel of experts covers the evolving role of targeted therapy in the management of EGFR-mutated NSCLC.

Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.

  AMA
Who Should Attend

This program is intended for oncologists and members of the multidisciplinary healthcare team that are involved in the care of patients with locally advanced or metastatic non-small cell lung cancer.

All Events

Expert Perspectives on the Evolving Treatment of EGFR-Mutated Advanced and Metastatic NSCLC

Upcoming Events

June

01

2024

6:30 PM - 8:30 PM Central Time (CT)

In-person

Hilton Chicago, 720 S Michigan Ave, Chicago, Illinois 60605

7:00 PM - 8:30 PM Central Time (CT)

Virtual

Faculty

ProCE Banner Faculty
Nicolas Girard, MD, PhD

Chair, Medical Oncology Department, Institut Curie
Paris, France
Professor, UVSQ, Paris Saclay University
Versailles, France

ProCE Banner Faculty
Natasha Leighl, MD, MMSC, FRCPC, FASCO

Lung Medical Oncology Site Lead
OSI Pharmaceuticals Foundation Chair
Princess Margaret Cancer Centre
Professor of Medicine, University of Toronto
Toronto, Canada

ProCE Banner Faculty
Karen L. Reckamp, MD, MS

Associate Professor
Medical Oncology and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, California

Topics

Latest Updates on (Neo)Adjuvant and 1L Systemic Therapy for Advanced/Metastatic NSCLC

  • Guideline recommendations for stage IIIA-C and IV NSCLC
    • Recommendations for EGFR-mutated NSCLC
  • Recent clinical trial data for:
    • EGFR alterations (eg, deletions, mutations, or insertions)

Considerations for Advanced/Metastatic NSCLC With Central Nervous System Metastases

EGFR TKI Mechanisms of Resistance

  • Known EGFR mutations affecting EGFR TKI efficacy
  • Systemic therapies for EGFR TKI therapy‒resistant/refractory disease
    • Current guidelines
    • Outcomes for systemic therapy in nonsquamous and/or squamous NSCLC

Highlights of Noteworthy ASCO 2024 Abstracts

Ongoing Studies and Investigational Therapies in EGFR-Mutated NSCLC

Closing Remarks and Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with advanced non-small cell lung cancer.

Target Audience
This program is intended for oncologists and members of the multidisciplinary healthcare team that are involved in the care of patients with locally advanced or metastatic non-small cell lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply to clinical practice the latest disease management strategies from ongoing clinical trials of targeted therapies, including recent updates to guidelines recommendations for individualizing a therapeutic strategy for the management of locally advanced and metastatic non-small cell lung cancer.  

  • Determine if individual patients with locally advanced and metastatic non-small cell lung cancer are candidates for an ongoing investigational clinical trial of a targeted therapy in the first- or subsequent-line based on need, due to inability or choice not to take standard of care treatments, unique mechanism of action, or the presence of specific EGFR genetic alterations.

  • Identify patients with EGFR-mutated locally advanced and metastatic non-small cell lung cancer that has progressed on third-generation EGFR TKI therapy that may be eligible for ongoing clinical trials evaluating combinations of currently available and novel targeted therapies, and counsel patients on the investigational agents or drug combinations and the potential for trial enrollment.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.